Convection-enhanced delivery of AAV2 in white matter-A novel method for gene delivery to cerebral cortex

Journal of Neuroscience Methods

Volumn 220, Issue 1, 2013, Pages 1-8

  Barua, N U ^a   Woolley, M ^a,b   Bienemann, A S ^a   Johnson, D ^a,b   Wyatt, M J ^a   Irving, C ^a,b   Lewis, O ^a,b   Castrique, E ^a   Gill, S S ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b RENISHAW PLC   (United Kingdom)

Author keywords

Cerebral cortex; Convection enhanced delivery; Gene therapy; White matter

Indexed keywords

ADENOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; FLOW RATE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE THERAPY; WHITE MATTER;

CEREBRAL CORTEX; CONVECTION-ENHANCED DELIVERY; GENE THERAPY; WHITE MATTER;

ANIMALS; CEREBRAL CORTEX; CONVECTION; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENTRICULAR; MAGNETIC RESONANCE IMAGING; NERVE FIBERS, MYELINATED; SWINE; TRANSGENES;

EID: 84884180892     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2013.08.011     Document Type: Article

References (23)

1. Bienemann A., White E., Woolley M., Castrique E., Johnson D.E., Wyatt M., et al. The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery. J Neurosci Methods 2012, 203:284-291.
2. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994, 91:2076-2080.
3. Bowles D.E., McPhee S.W., Li C., Gray S.J., Samulski J.J., Camp A.S., et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012, 20:443-455.
4. Bruce J.N., Fine R.L., Canoll P., Yun J., Kennedy B.C., Rosenfeld S.S., et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 2011, 69:1272-1279.
5. Fatouros P.P., Marmarou A. Use of magnetic resonance imaging for in vivo measurements of water content in human brain: method and normal values. J Neurosurg 1999, 90:109-115.
6. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589-595.
7. Gimenez F., Krauze M.T., Valles F., Hadaczek P., Bringas J., Sharma N., et al. Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 2011, 54(Suppl. 1):S189-S195.
8. Gurol M.E., Viswanathan A., Gidicsin C., Hedden T., Martinez-Ramirez S., Dumas A., et al. Cerebral amyloid angiopathy burden associated with leukoaraisosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 2012, [Epub ahead of print].
9. Kells A.P., Hadaczek P., Yin D., Bringas J., Varenika V., Forsayeth J., et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A 2009, 106:2407-2411.
10. Kunwar S., Chang S., Westphal M., Vogelbaum M., Sampson J., Barnett G., et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010, 12:871-881.
11. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59:459-466.
12. Lieberman D.M., Laske D.W., Morrison P.F., Bankiewicz K.S., Oldfield E.H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995, 82:1021-1029.
13. Mountcastle V.B. The columnar organization of the neocortex. Brain 1997, 120:701-722.
14. Mueller C., Flotte T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008, 15:858-863.
15. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
16. Prange M.T., Meaney D.F., Margulies S.S. Defining brain mechanical properties: effects of region, direction, and species. Stapp Car Crash J 2000, 44:205-213.
17. Raghavan R., Brady M., Chen Z., Broaddus W. Quantifying fluid infusions and tissue expansion in brain. IEEE Trans Bio-med Eng 2011, [Epub ahead of print].
18. Richardson R.M., Kells A.P., Rosenbluth K.H., Salegio E.A., Fiandaca M.S., Larson P.S., et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011, 19:1048-1057.
19. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006, 202:497-505.
20. Sbardella E., Petsas N., Tona F., Prosperini L., Raz E., Pace G., et al. Assessing the correlation between grey and white mayyer damage with motor and cognitive impairment in multiple sclerosis patients. PLoS One 2013, 8:e63250.
21. White E., Woolley M., Bienemann A., Johnson D.E., Wyatt M., Murray G., et al. A robust MRI-compatible system to facilitate highly accurate stereotactic administration of therapeutic agents to targets within the brain of a large animal model. J Neurosci Methods 2011, 195:78-87.
22. Yin D., Valles F.E., Fiandaca M.S., Bringas J., Gimenez F., Berger M.S., et al. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 2011, 54(Suppl. 1):S196-S203.
23. Zhang Z., Miyoshi Y., Lapchak P.A., Collins F., Hilt D., Lebel C., et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997, 282:1396-1401.